Daniel Carpenter1. Show Affiliations » 1. Harvard University, Cambridge, Massachusetts 02138, USA. dcarpenter@gov.harvard.edu
Abstract
Mesh： See more » Amines/adverse effectsAntibodies, Monoclonal, Humanized/adverse effectsBevacizumabDiet Fads/adverse effectsDietary Supplements/adverse effectsDietary Supplements/economicsDietary Supplements/standardsDisclosureDrug Approval/economicsDrug Approval/legislation & jurisprudenceDrug-Related Side Effects and Adverse ReactionsFederal GovernmentHumansPublic HealthTime FactorsTreatment FailureUnited StatesUnited States Dept. of Health and Human Services/legislation & jurisprudenceUnited States Food and Drug Administration/economicsUnited States Food and Drug Administration/legislation & jurisprudenceUnited States Food and Drug Administration/organization & administration
Substances： See more » 1,3-dimethylamylamineAminesAntibodies, Monoclonal, HumanizedBevacizumab
Year: 2012 PMID： 22575942 DOI： 10.1038/485169a
Source DB: PubMed Journal: Nature ISSN： 0028-0836 Impact factor: 49.962